Octreotide treatment improves multiple domains of cognitive performance in aged beagle dogs

Aging in dogs is accompanied by progressive cognitive decline and neuropathological changes that parallel key features of human brain aging and dementia, making canines a highly valuable naturally occurring model for studying aging and neurodegenerative disease. Across species, reduced growth hormone/insulin-like growth factor-1 (GH/IGF-1) signaling is associated with extended lifespan and preserved late-life cognition, whereas chronically elevated somatotropic activity is linked to deficits in memory, attention, and executive function. The effects of pharmacologic GH/IGF-1 suppression on cognition in naturally aging animal models remain unclear. We investigated whether attenuation of IGF-1 signaling with the long-acting somatostatin analog octreotide improves cognitive performance in aged dogs. Twenty-eight aged beagle dogs (7–15 years) experienced in neuropsychological testing were enrolled in a randomized, placebo-controlled study. After a 28-day baseline, dogs received either long-acting octreotide (Sandostatin LAR, 10 mg, i.m.) or placebo, followed by a wash-in interval and 28 days of post-treatment testing. A validated cognitive battery assessed executive function and cognitive flexibility (discrimination reversal), selective attention (variable oddity), and visuospatial working memory (variable delayed non-matching to position). Treated dogs demonstrated significantly improved performance relative to placebo across the three behavioral paradigms with the primary effect being reductions in response latency and task engagement. Pharmacologic IGF-1 suppression with octreotide improves cognitive response efficiency and engagement in aged dogs, particularly in executive and attentional domains. These results support a functional role for somatotropic signaling in late-life cognition and highlight the aged canine as a valuable translational model for geroscience-based interventions targeting age-related cognitive decline.

Authors

Publication Details

Journal
Frontiers in Veterinary Science
Published
2026-11-04
DOI
https://doi.org/10.3389/fvets.2026.1945789
Primary Topic
Growth Hormone and Insulin-like Growth Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Octreotide treatment improves multiple domains of cognitive performance in aged beagle dogs

Karen Greenwood, Michael L. LaCroix‐Fralish, Ashley P. Tovar, Celine-Lea Halioua-Haubold et al.
Frontiers in Veterinary Science
Growth Hormone and Insulin-like Growth Factors
article

Octreotide treatment improves multiple domains of cognitive performance in aged beagle dogs

Karen Greenwood, Michael L. LaCroix‐Fralish, Ashley P. Tovar, Celine-Lea Halioua-Haubold, Matthew Peloquin, Entonio Marietti, Dina L. Juarez-Salinas, Frances Chen, Elena Silva
article en

Abstract

Aging in dogs is accompanied by progressive cognitive decline and neuropathological changes that parallel key features of human brain aging and dementia, making canines a highly valuable naturally occurring model for studying aging and neurodegenerative disease. Across species, reduced growth hormone/insulin-like growth factor-1 (GH/IGF-1) signaling is associated with extended lifespan and preserved late-life cognition, whereas chronically elevated somatotropic activity is linked to deficits in memory, attention, and executive function. The effects of pharmacologic GH/IGF-1 suppression on cognition in naturally aging animal models remain unclear. We investigated whether attenuation of IGF-1 signaling with the long-acting somatostatin analog octreotide improves cognitive performance in aged dogs. Twenty-eight aged beagle dogs (7–15 years) experienced in neuropsychological testing were enrolled in a randomized, placebo-controlled study. After a 28-day baseline, dogs received either long-acting octreotide (Sandostatin LAR, 10 mg, i.m.) or placebo, followed by a wash-in interval and 28 days of post-treatment testing. A validated cognitive battery assessed executive function and cognitive flexibility (discrimination reversal), selective attention (variable oddity), and visuospatial working memory (variable delayed non-matching to position). Treated dogs demonstrated significantly improved performance relative to placebo across the three behavioral paradigms with the primary effect being reductions in response latency and task engagement. Pharmacologic IGF-1 suppression with octreotide improves cognitive response efficiency and engagement in aged dogs, particularly in executive and attentional domains. These results support a functional role for somatotropic signaling in late-life cognition and highlight the aged canine as a valuable translational model for geroscience-based interventions targeting age-related cognitive decline.

Frontiers in Veterinary ScienceVol. 13
Openalex Percentile: Top 12%
Growth Hormone and Insulin-like Growth Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon